PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: Value of static versus kinetic measures of fluorodeoxyglucose uptake

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2400-2409

  Dunnwald, Lisa K ^a   Doot, Robert K ^a   Specht, Jennifer M ^a   Gralow, Julie R ^a   Ellis, Georgiana K ^a   Livingston, Robert B ^c   Linden, Hannah M ^a   Gadi, Vijayakrishna K ^a   Kurland, Brenda F ^b   Schubert, Erin K ^a   Muzi, Mark ^a   Mankoff, David A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KINETIC MEASURE; LYMPH NODE METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; STATIC STANDARDIZED UPTAKE VALUE; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KINETICS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 79954611821     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2649     Document Type: Article

References (43)

1. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-88. (Pubitemid 10203423)
2. Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, et al. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constant and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metabol 1985;5:179-92. (Pubitemid 15123203)
3. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11. (Pubitemid 23332245)
4. Krak NC, Van der Hoeven JJ, Hoekstra OS, Twisk JW, Van der Wall E, Lammertsma AA. Measuring [(18) F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging 2003;30:674-81. (Pubitemid 36612949)
5. Lee JH, Rosen EL, Mankoff DA. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2-response to therapy, other indications, and future directions. J Nucl Med 2009;50:738-48.
6. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507-16. (Pubitemid 19006431)
7. Beahrs OH. Staging of cancer. CA Cancer J Clin 1991;41:121-5.
8. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008;26:814-9. (Pubitemid 351265335)
9. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-81. (Pubitemid 16120734)
10. Machiavelli MR, Romero AO, Perez JE, Lacava JA, Domínguez ME, Rodríguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-31. (Pubitemid 29090716)
11. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998;176:502-9. (Pubitemid 29056639)
12. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-14. (Pubitemid 39663314)
13. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008;26:4449-57.
14. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS. How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging 2006;33 Suppl 13: 16-21.
15. Doot RK, Dunnwald LK, Schubert EK, Muzi M, Peterson LM, Kinahan PE, et al. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med 2007;48:920-5. (Pubitemid 46909920)
16. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-9. (Pubitemid 34286345)
17. Tseng J, Dunnwald LK, Schubert EK, Link JM, Minoshima S, Muzi M, et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 2004;45:1829-37. (Pubitemid 47618439)
18. Lewellen TK, Kohlmyer S, Miyaoka R, Schubert S, Stearns C. Investigation of the count rate performance of the General Electric ADVANCE poistron emission tomograph. IEEE Trans Nucl Sci 1995;42:1051-7.
19. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8. (Pubitemid 17024868)
20. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85. (Pubitemid 28363030)
21. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics 2002;58:657-64. (Pubitemid 35001484)
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
23. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B 1972;34:187-220.
24. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. New York: John Wiley & Sons; 2002.
25. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27:535-41.
26. Avril N, Rosè CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495-502.
27. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16. (Pubitemid 32104770)
28. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007;73:1151-7. (Pubitemid 351396527)
29. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008;38:250-8. (Pubitemid 351583988)
30. Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009;96:166-70.
31. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007;102:75-84. (Pubitemid 46294965)
32. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998;39:250-4. (Pubitemid 28114512)
33. Mankoff DA, Muzi M, Krohn KA. Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method? Mol Imaging Biol 2003;5:281-5. (Pubitemid 38100889)
34. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000;27:643-6.
35. Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, et al. Metabolic and vascular features of dynamic contrastenhanced breast magnetic resonance imaging and (15) O-water positron emission tomography blood flow in breast cancer. Acad Radiol 2008;15:1246-54.
36. Mulani N, Brandon D, Barron B, Lamki L, Gould L. The standard uptake value (SUV). Is it necessary for diagnosing malignant tissue by F-18-FDG PET? Clin Positron Imaging 1998;1:243.
37. Zasadny K, Wahl R. Regional FDG uptake versus blood flow in untreated primary breast cancers. J Nucl Med 1993;34:74P.
38. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006;239:361-74.
39. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, et al. Invasive breast cancer: predicting disease recurrence by using highspatialresolution signal enhancement ratio imaging. Radiology 2008;248:79-87.
40. Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, et al. SUV varies with time after injection in (18) F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 2003;44:1044-50. (Pubitemid 39663378)
41. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18) F-FDG PET. J Nucl Med 2005;46:1819-24. (Pubitemid 46196643)
42. Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006;47:1440-6. (Pubitemid 47544929)
43. O'Sullivan F. Imaging radiotracer model parameters in PET: a mixture analysis approach. IEEE Tran Med Imaging 1993;12:399-412.